Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Moderna by Quarter
Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current payables / liabilities to partner ($M) ($M)
Merck Moderna: $0M in Q2 2026, down 100.0% from a year earlier. That is the lowest of the 12 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Moderna (intismeran autogene / mRNA-4157 Individualized Neoantigen Therapy) — Current payables / liabilities to partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0 | -100.0% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | -100.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 13 | -77.2% | Form 10-Q (filed 2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 13 | -80.9% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 22 | -69.9% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 37 | -48.6% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 57 | -9.5% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 68 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 73 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 72 | – | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 63 | +800.0% | Form 10-K (filed 2025-02-25) ↗ |
| Q4 2022 | Dec 31, 2022 | 7 | – | Form 10-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck Moderna ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-moderna-ap-cur
See every metric in the Merck KPI table. Data updated Oct 26, 2026.